China cancer monoclonal antibodies market is estimated to grow at a CAGR of 11.6% during the forecast period. Rising new cancer incidences is the major factor driving the adoption of monoclonal antibodies therapeutics in the country. As per the World Health Organization (WHO), nearly 4.3 million new cancer incidences were reported in 2018. Lung cancer accounted for 18.1%, colorectal (12.2%), stomach (10.6%), liver (9.2%), breast (8.6%), and others (41.4%) of all new cancer incidences in 2018. This is leading to increasing demand for monoclonal antibodies for cancer therapeutics as targeted therapy. These monoclonal antibodies have a particular target on a cancer cell that intends to discover, attach to, and attack. However, some monoclonal antibodies work as immunotherapy as they support to make the response of the immune system better, which in turn, supports the body to discover and attack cancer cells more potentially.
Get Free Sample link @ https://www.omrglobal.com/request-sample/china-cancer-monoclonal-antibodies-market
China cancer monoclonal antibodies market is segmented based on type and application. Based on type, the market is classified into naked, conjugated, and others. Based on the application, the market is classified into breast cancer, liver cancer, blood cancer, brain cancer, colorectal cancer, and others. Naked monoclonal antibodies are the most common form of antibodies used for the treatment of cancer. Most naked monoclonal antibodies bind to antigens that are normally multiple on the surface of cancer cells compared to healthy cells. BYVASDA (bevacizumab), ERBITUX (cetuximab), Trastuzumab (Herceptin), and MabThera/Rituxan (rituximab) are some naked monoclonal antibody drugs that are commonly used for cancer treatment in the country. The increasing launches of naked monoclonal antibodies biosimilars in the country are further leveraging the share of this segment.
A full report of China Cancer Monoclonal Antibodies Market available @ https://www.omrglobal.com/industry-reports/china-cancer-monoclonal-antibodies-market
- Market Coverage
- Market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered- By Source, By Product Type, By Applications
- Competitive Landscape- Archer Daniels Midland Co., Ingredion Inc., Kerry Group Plc, Cargill Inc., and others
Market Segmentation
China Cancer Monoclonal Antibodies Market by Type
- Naked
- Conjugated
- Others (Bispecific)
China Cancer Monoclonal Antibodies Market by Application
- Breast Cancer
- Liver Cancer
- Blood Cancer
- Brain Cancer
- Colorectal Cancer
- Others
Company Profiles
- Amgen Inc.
- Anhui Anke Biotechnology (Group) Co., Ltd.
- AstraZeneca plc
- CStone Pharmaceuticals
- Genor BioPharma Co., Ltd.
- Harbour BioMed (HBM)
- Innovent Biologics, Inc.
- Merck & Co., Inc.
- Pfizer Inc.
- Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- Viva Biotech (Shanghai) Ltd.
- Zhejiang Hisun Pharmaceutical Co., Ltd.
The Report Covers
- Comprehensive research methodology of the China cancer monoclonal antibodies market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the China cancer monoclonal antibodies market.
- Insights about market determinants which are stimulating the China cancer monoclonal antibodies market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/china-cancer-monoclonal-antibodies-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404
